Cargando…

Compounds that select against the tetracycline resistance efflux pump

We developed a competition-based screening strategy to identify compounds that invert the selective advantage of antibiotic resistance. Using our assay, we screened over 19,000 compounds for the ability to select against the TetA tetracycline resistance efflux pump in E. coli and identified two hits...

Descripción completa

Detalles Bibliográficos
Autores principales: Stone, Laura K., Baym, Michael, Lieberman, Tami D., Chait, Remy, Clardy, Jon, Kishony, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069154/
https://www.ncbi.nlm.nih.gov/pubmed/27642863
http://dx.doi.org/10.1038/nchembio.2176
_version_ 1782460890490077184
author Stone, Laura K.
Baym, Michael
Lieberman, Tami D.
Chait, Remy
Clardy, Jon
Kishony, Roy
author_facet Stone, Laura K.
Baym, Michael
Lieberman, Tami D.
Chait, Remy
Clardy, Jon
Kishony, Roy
author_sort Stone, Laura K.
collection PubMed
description We developed a competition-based screening strategy to identify compounds that invert the selective advantage of antibiotic resistance. Using our assay, we screened over 19,000 compounds for the ability to select against the TetA tetracycline resistance efflux pump in E. coli and identified two hits: β-thujaplicin and disulfiram. Treating a tetracycline resistant population with β-thujaplicin selects for loss of the resistance gene, enabling an effective second-phase treatment with doxycycline.
format Online
Article
Text
id pubmed-5069154
institution National Center for Biotechnology Information
language English
publishDate 2016
record_format MEDLINE/PubMed
spelling pubmed-50691542017-03-19 Compounds that select against the tetracycline resistance efflux pump Stone, Laura K. Baym, Michael Lieberman, Tami D. Chait, Remy Clardy, Jon Kishony, Roy Nat Chem Biol Article We developed a competition-based screening strategy to identify compounds that invert the selective advantage of antibiotic resistance. Using our assay, we screened over 19,000 compounds for the ability to select against the TetA tetracycline resistance efflux pump in E. coli and identified two hits: β-thujaplicin and disulfiram. Treating a tetracycline resistant population with β-thujaplicin selects for loss of the resistance gene, enabling an effective second-phase treatment with doxycycline. 2016-09-19 2016-11 /pmc/articles/PMC5069154/ /pubmed/27642863 http://dx.doi.org/10.1038/nchembio.2176 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Stone, Laura K.
Baym, Michael
Lieberman, Tami D.
Chait, Remy
Clardy, Jon
Kishony, Roy
Compounds that select against the tetracycline resistance efflux pump
title Compounds that select against the tetracycline resistance efflux pump
title_full Compounds that select against the tetracycline resistance efflux pump
title_fullStr Compounds that select against the tetracycline resistance efflux pump
title_full_unstemmed Compounds that select against the tetracycline resistance efflux pump
title_short Compounds that select against the tetracycline resistance efflux pump
title_sort compounds that select against the tetracycline resistance efflux pump
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069154/
https://www.ncbi.nlm.nih.gov/pubmed/27642863
http://dx.doi.org/10.1038/nchembio.2176
work_keys_str_mv AT stonelaurak compoundsthatselectagainstthetetracyclineresistanceeffluxpump
AT baymmichael compoundsthatselectagainstthetetracyclineresistanceeffluxpump
AT liebermantamid compoundsthatselectagainstthetetracyclineresistanceeffluxpump
AT chaitremy compoundsthatselectagainstthetetracyclineresistanceeffluxpump
AT clardyjon compoundsthatselectagainstthetetracyclineresistanceeffluxpump
AT kishonyroy compoundsthatselectagainstthetetracyclineresistanceeffluxpump